As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the…
In Conversation
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment…
What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within…
